Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 203 participants.
Also called NCT03829657
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 203 participants
- Sponsor
- Theravance Biopharma
- Registry
-
NCT03829657 -
2018-003941-41
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Bulgaria, Canada, Denmark, Estonia, France, Germany, Hungary, Israel, Italy, New Zealand, Poland, Portugal, Russia, Spain, Ukraine, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT03829657. Randomized; triple masking; primary purpose treatment. Start 2019-02-22 (actual); primary completion 2021-11-10 (actual). Results posted on 2023-01-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
- Acronym
- REDWOOD
- Condition
- Symptomatic Neurogenic Orthostatic Hypotension
- Condition
- MSA
- Condition
- Parkinson's Disease (PD)
- Condition
- Pure Autonomic Failure (PAF)
- Intervention (Drug)
- ampreloxetine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Theravance Biopharma
Record details
- Record id
cardio:ct-nct03829657- Content hash
c96c917d7b632935061158ad2e4d8cf2f9da925a2042cdb9f5d259628fc358de